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During the past decades, a growing interest has been raised in evaluating nontuberculous mycobacteria (NTM) in patients with
noncystic fibrosis bronchiectasis (NCFBE). This paper reviews several aspects of the correlations between NTM and NCFBE,
including pathogenesis, radiological features, diagnosis, and management. Bronchiectasis and NTM lung disease are connected,
but which one comes first is still an unresolved question. The rate of NTM lung disease in NCFBE varies through the studies, from
5% to 30%.Themost frequent species isolated is MAC. NCFBE patients affected by NTM infection frequently present coinfections,
including both other different NTM species and microorganisms, such as P. aeruginosa. Once a diagnosis of NTM disease has been
reached, the initiation of therapy is not always mandatory. NTM species isolated, patients’ conditions, and disease severity and
its evolution should be considered. Risk factors for disease progression in NCFBE patients with NTM are low body mass index,
cavitary disease, consolidations, and macrolide resistance at presentation.
1. Introduction
Nontuberculous mycobacteria (NTM) comprise mycobac-
teria other than Mycobacterium tuberculosis complex and
M. leprae. Until now, more than 160 species have been
isolated, many of which may be pathogen for humans. In
1959, Runyon proposed a classification of NTM into four
main categories: group I of slow-growing photochromogens
(e.g., M. kansasii and M. simiae), group II of slow-growing
scotochromogens (e.g., M. szulgai and M. xenopi), group
III of slow-growing nonphotochromogens (e.g., M. avium
complex and M. malmoense), and group IV of the rapid
growers (e.g., M. fortuitum, M. chelonae, and M. abscessus)
[1].
A simplified classification of NTM is based on the
rate of growth: according to this criterion, they have been
divided into slowly and rapidly growing species. The first
group takes more than 7 days to complete the growing in
culture (e.g., Mycobacterium avium complex—MAC—and
M. kansasii), while rapidly growing take less than 7 days (e.g.,
M. abscessus).
NTM are ubiquitous in the environment and have been
isolated from soil and water, which are the presumed sources
of infection. Until now, there is no evidence of animal-to-
human or human-to-human transmission. Recent data seem
to reveal the possibility of indirect human-to-human trans-
mission of M. abscessus subspecies massiliense in patients
affected by cystic fibrosis (CF). Bryant and colleagues have
performed a genetic analysis ofM. massiliense isolates in CF
patients and have found near-identical isolates in different
patients attending their centre; genetic data have revealed
frequent transmission of multidrug resistant M. massiliense
[2]. Although the authors cannot demonstrate the exact way
of transmission, they postulate that it could be indirect. A
single recent case report from United Kingdom suggests the
possibility of human-to-human transmission of M. kansasii.
A woman and her husband in London were infected by
identical strains of M. kansasii, while no common source of
infection could be found [3].
The exact prevalence of NTM disease is unknown
because reporting is not mandatory in many countries and
discrimination between colonization and active disease can
Hindawi Publishing Corporation
BioMed Research International
Volume 2015, Article ID 197950, 8 pages
http://dx.doi.org/10.1155/2015/197950
2 BioMed Research International
be challenging. Certainly, the rates of isolation of NTM are
increasing in the last years because of many factors, including
the progress in diagnostic techniques and the increasing
attention to this topic. The prevalence of NTM infection in
the United States of America (USA) from 2004 to 2006 raised
from 1.4 to 6.6 per 100,000 persons [4]. In England, Wales,
and Northern Ireland, the rate of all NTM reports increased
from 0.9 per 100,000 population in 1995 to 2.9 per 100,000 in
2006 [5].
NTM disease usually affects patients with chronic
lung disease (e.g., chronic obstructive pulmonary disease—
COPD—or CF) but it has been also described in healthy
individuals [6]. During the past decades, a growing interest
has been raised in evaluating NTM in patients with non-CF
bronchiectasis (NCFBE). Reports of NTM lung infection in
NCFBE patients are increasing in the last years, although the
exact pathogenesis of NTM infection in this population is not
well known, along with its impact on clinical outcomes [7].
The aim of this paper is to review several aspects of the
correlations betweenNTM andNCFBE, including pathogen-
esis, radiological findings, diagnosis, and management.
2. Pathogenesis of NTM in
Non-CF Bronchiectasis
The three major factors involved in the pathogenesis of NTM
infection are the exposure, a damage substrate, and a possible
immune defect.
2.1. Exposure. NTM are ubiquitous in the environment, so,
in theory, all people can be exposed to them. The way of
contact with NTM is probably inhalation, most likely via
aerosols from natural surface water or hot water systems.
Some conditions may increase the risk of lung exposure.
Microaspiration of ingested contaminated water can be a way
of access for NTM to the lung. Patients affected by gastroe-
sophageal reflux (GORD) or by lung disease associated with
GORD—such as bronchiectasis—might bemore predisposed
to NTM lung infection [8]. However, in a group of patients
affected by NCFBE, no difference in the presence or absence
of gastroesophageal reflux has been found between patients
affected or not affected by NTM disease [9].
2.2. Substrate. NTM lung disease is common in structural
lung disease, such as CF, bronchiectasis, and COPD. A
structural damage, as an injured epithelium or a deficit in
mucociliary clearance, is a predisposing factor to NTM lung
infection. MAC has the ability to adhere to the extracellular
matrix that is exposed in areas of epithelial damage and in
areas where fibrous mucus is poorly cleared, due to impaired
mucociliary clearance [10].
2.3. Defective Immunity. Despite the fact that NTM are
ubiquitous in the environment, relatively few individuals
develop NTM lung disease, suggesting a possible intrinsic
predisposition, such as a deficit in immunity response.
The pathogenesis of NTM lung disease involves many
components of both innate and adaptive immunity. The
innate immune system is the first line of defence against
mycobacteria. It involved many pattern recognition recep-
tors, such as toll-like receptors (TLR) to help identifica-
tion, phagocytosis, and activation of defense mechanisms
against mycobacteria. TLRs help begin rapid defense mech-
anism, such as phagocytosis and activation of antimicro-
bial activity and modulating adaptive immune responses
[11].
Macrophages ingest mycobacteria and deliver them to
degradative compartments where they are eliminated [12].
Macrophages stimulate cytokines, such as interleukin-12,
which in turn upregulates interferon- (IFN-) 𝛾 and tumor
necrosis factor-alpha (TNF-𝛼) [13]. Cytokines recruit and
stimulate T-lymphocytes and Natural Killer cells to help kill
mycobacteria [14]. Some data about association with specific
human leukocyte antigen (HLA) alleles exist. Kubo et al.
founded an association between HLA-DR6/HLA-DQ4 and
MACpulmonary disease and associations betweenHLA-A26
and deterioration of nodular-bronchiectatic MAC infection
[15]. The importance of these factors in immune response is
confirmed by the increased number of NTM diseases in case
of defect in one of them. Genetic defects in IFN-𝛾 signaling
are rare disorders associated with high risk of developing dis-
seminating NTM infection [16]. Some evidences exist about
a high risk of developing active tuberculosis (TB) in patients
with latent TB infection undergoing anti-TNF-𝛼 therapy
as well as the development of NTM disease during this
therapy [17, 18]. In a recent study performed on mice, Renna
et al. reported a possible association between long-term
azithromycin treatment and development of NTM infec-
tion in CF patients [19]. They supposed that azithromycin
impaired lysosomal degradation of both autophagosomes
and phagosomes and can lead to failure of intracellular killing
of mycobacteria and development of chronic infection with
M. abscessus in mouse models. In HIV-positive patients, dis-
seminated NTM infection usually takes place if CD4+ T-cell
count is very low, suggesting the importance of cell-mediated
immunity in antimycobacterial defense [20]. Furthermore,
the initiation of antiretroviral therapy in case of NTM lung
disease may be followed by development of the “immune
reconstitution inflammatory syndrome,” due to restoration
of pathogen-specific immune responses. In the majority of
cases, this syndrome associatedwithMACpresentswith fever
and lymphadenopathy or painful lymphadenitis [21]. NTM
pulmonary disease is frequent in women with a similar body
habitus, characterized by elderly age, low body mass index,
bronchiectasis, and centrilobular nodules, a condition noted
with the acronym of LadyWindermere syndrome [22]. Other
conditions frequently observed in patients affected by NTM
pulmonary disease are scoliosis, pectus excavatum, mitral
valve prolapse, and cystic fibrosis transmembrane conduc-
tance regulator (CFTR) mutations. Despite this association,
no common immune defect has been found in these patients,
in terms of neither cytokine production nor cell-mediated
immunity [23].
Mutations of CFTR gene have been found in many
patients with bronchiectasis andMAC lung disease; although
these patients have not a diagnosis of CF, it seems that
they have some defects in bronchial mucosal ion and in
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water transport. These factors might be associated with
development of bronchiectasis [23, 24].
Other evidences about possible genetic factors contribut-
ing to host susceptibility to NTM lung infection come from
a retrospective review of six familial clusters of pulmonary
NTM infection with at least two members affected by NTM
lung infection [25].Themajority of patientswere nonsmokers
women, scoliosis was present in 31% of patients, and CFTR
mutation without CF diagnosis was found in 42% of affected
individuals. Furthermore, another common condition asso-
ciated with bronchiectasis in patients with NTM infection is
alpha-1 antitrypsin deficiency [26]. Systemic compromised
host defenses, such as diabetes mellitus, malignancy, or
transplant recipients, have been shown to be predisposing
factors in the development of NTM lung disease, although
a clear and definitive mechanism has not been yet identified
[27–29].
3. NTM and Non-CF Bronchiectasis:
Who Comes First?
Undoubtedly, bronchiectasis and NTM lung disease are con-
nected, but which one comes first is an unresolved question
so far. In some diseases, such as CF or posttuberculosis
bronchiectasis, it seems reasonable that anatomic alterations
of bronchi precede NTM infection [30]. On the other hand,
few experiences have reported a possible role of NTM
infection in causing bronchiectasis. Okumura et al. reported
the case of a woman in which pulmonary MAC lesions
seemed to precede the central bronchial lesion with later
development of bronchiectasis [31]. Fujita and colleagues
retrospectively studied pathological abnormalities in patients
undergoing surgical resection for MAC lung disease and
bronchiectasis [32]. Destruction of bronchial cartilage and
smooth muscle layer, airways’ granulomas, and ulcerated
bronchial mucosa were found. The authors assumed that
cartilage and smooth muscle destruction, caused by MAC,
could result in bronchiectasis and that granulomas constitute
the evidence that bronchiectasis is not antecedent but a
consequence of chronic MAC infection.
4. Prevalence and Radiological
Manifestations of NTM Species
The rate of NTM lung disease, according to American Tho-
racic Society (ATS) criteria, in patients with bronchiectasis
varies through the studies from 5% to 10% and to 30% [9, 33,
34].
In a recent meta-analysis, the overall prevalence of
NTM in patient with bronchiectasis was 9.3% [5]. In CF-
bronchiectatic patients, prevalence of NTMvaries from 5% to
20% through different studies [35, 36]. In a multicentre study
performed in US in CF patients, the prevalence was 13% with
range by centres from 7 to 24% [37].
The most frequent species isolated in bronchiectatic
patients is MAC, with a percentage up to 50% and also
80% of the total of NTM [9, 39, 40]. The rate of isolation
Figure 1: Fibrocavitary form ofMycobacterium avium lung disease.
of different species varies from study to study. In an obser-
vational prospective study performed in Korea analysing
105 bronchiectatic patients, MAC constituted 50% of NTM
isolated [39]. Other species isolated were M. abscessus
(39%), M. kansasii (3%), and M. fortuitum (3%). In another
observational prospective study performed in London, apart
from MAC (isolated in 53% of 30 patients), other NTM
isolated were M. kansasii (28%), M. chelonae (1%), M.
malmoense (1%), M. fortuitum (1%), and M. simiae (only
one patient) [41]. NTM lung infection can present itself
with different radiological patterns. Two major radiological
patterns have been described: the fibrocavitary form and
the nodular/bronchiectatic one. The fibrocavitary form is
characterized by areas of increased opacity and cavitations,
usually localized in the upper lobes, with or without calcifica-
tion; see Figure 1. Apical pleural thickening and fibrosis with
volume loss and traction bronchiectasis are frequent [39].
Lower lobe involvement, adenopathies, and pleural effusion
are uncommon. The radiologic presentation is similar to
postprimary tuberculosis; however, NTM infection usually
progresses more slowly than active tuberculosis [39, 42].
Wallace et al. reported some differences between NTM
disease and tuberculosis. NTM tend to cause thin-walled
cavities with less surrounding parenchymal infiltrate, have
less bronchogenic but more contiguous spread of disease,
and produce more marked involvement of pleura over the
involved areas of the lungs [43]. Patients affected by these
forms of NTM infection are typically elderly men with
underlying lung disease [39].
The second radiologic pattern consists in cylindrical
bronchiectasis and multiple small centrilobular nodules,
localized especially in middle lobe and lingual; see Figure 2
[39, 44]. Reich and Johnson first used the term “Lady
Windermere syndrome” to describe this pattern of NTM
lung disease in elderly white woman without underlying
lung disease symptomatic for chronic cough [22]. One study
compared different radiological presentations of NTM lung
disease: MAC was the most common species isolated in
bronchiectatic (42%) and consolidative (43%) forms and M.
chelonae/M. abscessus the most common in cavitary form
(37%) [45]. Furthermore, in the same study,M.kansasii seems
more common in cavitary (15%) and consolidative (13%)
pattern than in bronchiectatic pattern (9%).
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Figure 2: Nodular/bronchiectatic form of nontuberculous mycobacterial lung disease. Axial (a) and coronal (b) computed tomography
images demonstrating focal bronchiectasis in both the right middle lobe and lingula, characteristic of Lady Windermere syndrome [38].
5. Coinfection of NTM and Other Pathogens in
Non-CF Bronchiectasis
Patients affected by NTM infection frequently present some
coinfections, including both other different NTM species
and microorganisms. P. aeruginosa is the most common
copathogen isolated, with a percentage ranging from 27% to
52% [40, 46]. Infection with P. aeruginosa has been reported
to worsen lung functions in bronchiectasis, but, in a recent
study, no differences were reported concerning this aspect
between patients infected and those not infected with this
pathogen [46, 47]. Wickremasinghe and colleagues, in a ret-
rospective analysis of 100 bronchiectatic patients performed
in Brompton, found that the first pathogen isolated together
with NTM was P. aeruginosa (52% of patients with multiple
isolations), but only a quarter was chronic isolation [40]. In
the same study, the second copathogen was S. aureus with
a percentage of 28%, followed by H. influenzae (12%), A.
fumigatus (4%), C. albicans (8%), and S. maltophilia (4%).
Wallace and colleagues, in a prospective study of 26 patients
affected by MAC infection, reported also Nocardia spp. (12%
of patients) and M. fortuitum [43]. Also M. abscessus is
described in these patients [30]. Another interesting point
is that patients with nodular bronchiectasis pattern seem to
frequently have multiple and/or repeated MAC infections
with multiple isolated genotypes. On the other hand, patients
with cavitary patterns are usually infected with one single
strain [48]. Coinfection of NTM and M. tuberculosis is
described also in immunocompetent patients, but no data are
available in NCFBE [49, 50].
6. Challenges in NTM Diagnosis in Patients
with Non-CF Bronchiectasis
NTM lung disease diagnosis is often difficult to establish,
because of a frequent possibility of sample contamination.
Furthermore, the respiratory tract can be infected with NTM
without clear symptoms/signs of active disease, a condition
that has been named colonization; however, there are no
data proving that colonization is not a slowly progressive
infection [30]. According to ATS guidelines, the diagnosis of
NTM lung disease is based on specific criteria: two clinical
criteria (pulmonary symptoms with compatible radiologic
pattern and exclusion of other diagnoses) and one among the
microbiological findings [30]. In light of the high probability
of sample contamination, ATS criteria require more than
one positive sample for diagnosis. One exception is patients
with classic symptoms and radiologic pattern of nodu-
lar/bronchiectatic alterations without sputum production.
According to ATS guidelines, the identification of NTM in
one bronchoscopic specimen, especially MAC, is considered
adequate in this specific type of patients for the diagnosis of
NTM lung disease [30]. Onemore consideration is that NTM
isolation in patients with CF is reported to be particularly
difficult to culture if P. aeruginosa colonization is present
[51]. So far, no studies are available in non-CF bronchiectasis
patients evaluating difficulties in NTM isolation in case of a
P. aeruginosa coinfection.
Differently from TB, in which transbronchial needle
aspiration (TBNA) has a possible role in diagnosis, only
few data exist about NTM infection. One study assessed
the utility of endobronchial ultrasound-guided- (EBUS-)
TBNA for the diagnosis of suspected granulomatous medi-
astinal lymphadenopathy [52]. Low et al. retrospectively
reviewed 13 cases of suspected granulomatous mediasti-
nal lymphadenopathy undergoing EBUS-TBNA, which was
diagnostic in 9 of them (69%) with a final diagnosis of
TB/NTM.
In specialized laboratories, molecular tests are available
for rapid identifications of most common NTM species.
Sequencing of genomic targets (such as 16S rRNA) allows
accurate and rapid identification, even if some technical lim-
itations exist, such as in case of samples with polymicrobial
patterns and the deficiencies in public sequence databases
[53].
BioMed Research International 5
Table 1: Treatment recommendations for nontuberculous mycobacteria, according to 2007 AmericanThoracic Society Guidelines.
Initial therapy for
nodular/bronchiectatic disease Initial therapy for cavitary disease
Severe disease or previously
treated disease
Mycobacterium
avium complex
Clarithromycin 1,000mg TIW or
azithromycin 500–600mg TIW
Ethambutol 25mg/kg TIW
Rifampin 600mg TIW
Clarithromycin 500–1,000mg/d or
azithromycin 250–300mg/d
Ethambutol 15mg/kg/d
Rifampin 450–600mg/d
±Streptomycin or amikacin or none
Clarithromycin 500–1,000mg/d
or azithromycin 250–300mg/d
Ethambutol 15mg/kg/d
Rifabutin 150–300mg/d or
rifampin 450–600mg/d
±Streptomycin or amikacin
Mycobacterium
kansasii
Rifampin 10mg/kg/d (maximum 600mg/day)
Ethambutol 15mg/kg/d
Isoniazid 5mg/kg/d (maximum 300mg)
Pyridoxine 50mg/d
TIW: three times in a week; d: day.
7. Treatment of NTM in
Non-CF Bronchiectasis
Once a diagnosis of NTM disease has been reached, the
initiation of therapy is not always mandatory. NTM therapy
is usually based on a prolonged treatment with at least two
drugs leading to several side effects. In view of this, a risk-
benefit evaluation should be carefully considered in each
patient before deciding whether to treat or not an NTM
infection. First of all, it should be considered which NTM
species has been isolated, while clinicians should knowwhich
NTM species are more likely to be pathogen for humans.
M. kansasii is considered one of the most virulent species
and M. fortuitum is one of the less virulent ones, while
species as M. gordonae and M. terrae are usually considered
contaminants [30]. After that, clinicians should consider
patients’ conditions, evaluating disease severity, its evolution,
and tolerability of drugs. Finally, the diagnosis of NTM lung
infection in patients affected by bronchiectasis is crucial in
the management of these patients because previous data have
shown the role of these pathogens in worsening preexisting
bronchiectasis [54, 55].
Radiological and clinical presentations are crucial to
determine schemes and duration of treatment. Patients
with more cavities, consolidations, and more severe and
widespread bronchiectasis are more likely to require treat-
ment [40]. Lee et al. evaluated retrospectively computed
tomography (CT) scans of 399 patients with nodular-
bronchiectatic form of MAC disease [7]. The presence of
cavity and consolidation at initial CT was independent
factors associated with disease progression and treatment
requirements.They suggest that, in patientswho initiallywere
not candidates for treatment, a radiological progression of the
disease later on could be a criterion for therapy.
Because of the fact that themajority of studies are focused
on MAC, several guidelines recommendations concerning
other NTM species tend to be based on MAC findings.
In terms of drug choice, ATS guidelines provide ther-
apeutic schemes specific for some pathogen and general
indications for others, such as rapidly growing mycobacteria;
see Table 1.
Because of the known discrepancy between in vitro
and in vivo drug susceptibility, the only drugs for which
susceptibility of MAC should be evaluated are macrolides
(azithromycin or clarithromycin) [56]. Rifampin should also
be tested forM. kansasii. In case of drug-resistant NTM, the
choice of drugs is based on in vitro susceptibility and expert
opinion. One general rule is that macrolide monotherapy
should be absolutely avoided in order to prevent the emer-
gence of resistances.
For most patients with nodular-bronchiectatic MAC
disease, intermittent, three-time weekly therapy is recom-
mended [30]. In case of severe nodular/bronchiectatic disease
or fibrocavitary presentation, a more aggressive regimen is
recommended. According to ATS guidelines, two-drug reg-
imen (macrolide and ethambutol) is acceptable only in case
of nodular/bronchiectaticMACdisease if drug intolerance or
mild disease is present.
In CF patients who are candidates for macrolide
monotherapy, it is recommended to have sputum cultured
for NTM before and during therapy. Furthermore, patients
with repeated isolation of NTM should not receive macrolide
monotherapy [30]. No specific recommendations exist for
NCFBE, but it seems reasonable to have a similar behavior,
in particular for subjects with a past history of NTM iso-
lation [57]. Differently from M. tuberculosis, therapy with
fluoroquinolones for bronchiectatic exacerbations does not
seem to be a risk factor for delayed diagnosis of NTM or
fluoroquinolonesNTMresistance, although there are no clear
data about it [57].
8. Risk Factors for Treatment
Failure and Follow-Up
In patients with nodular/bronchiectatic MAC disease under-
going therapy, sputum conversion is frequently achieved,
without the development of resistances. In a retrospec-
tive review evaluating the efficacy of macrolide/azalide-
containing regimens for nodular/bronchiectatic MAC lung
disease, sputum conversion to culture negative occurred in
86% of patients and nobody developed macrolide resistance
during treatment [58]. In the same study, microbiologic
recurrences occurred in 48% of patients who completed
treatment, of which 75% were reinfected with the isolation
of new MAC genotypes and 25% showed true relapse with
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recurrence of the pretreatment MAC genotype. True relapses
isolates occurred significantly earlier after completion of
therapy than reinfection isolates: 6.2 months versus 17.5
months. In a prospective observational study about MAC
lung disease in patients with nodular bronchiectasis, relapse
was rare in patients who are culture negative for more than
ten months of appropriate treatment and most infections
at this time are caused by new strains (85% of subsequent
infection). On the other hand, most of the infections in
patients who were culture negative for less than ten months
were a relapse (86% of infections), rather than new infection
[59]. No late isolates were macrolide resistant in both studies.
Noncompliance to therapy has to be carefully evaluated in
case of treatment failure. Some studies evaluated risk fac-
tors for disease progression in nodular/bronchiectatic MAC.
Kitada et al. performed an observational retrospective study
in 72 patients with nodular/bronchiectatic MAC lung disease
and showed that risk factors for disease progression were
low body mass index, cavitary disease, consolidations, and
macrolide resistance at presentation [60]. In another recent
observational retrospective study, Zoumot et al. showed that
chronic pulmonary aspergillosis, cavitation within nodules,
and emphysema at presentation are associated with increased
mortality in NCFBE affected by MAC infection [46].
MAC disease in nodular/bronchiectatic patients is a slow
but progressive long-term infection [60].
Considering that relapse or new infections are possible
after treatment, follow-up of these patients is mandatory
during and after therapy. Patients under antibiotics therapy
for NTM should be closely monitored, with sputum exam
and visit, to assess response to therapy and possible side
effects. Also patients who do not receive treatment should be
monitored to evaluate eventual disease progression.
Some reports exist about the role of fluorine-18 flu-
orodeoxyglucose positron-emission tomography/computed
tomography (F-18 FDG PET/CT) in evaluation of treatment
response. Sato et al. reported a case of disseminated MAC
infection and a FDG PET/CT performed after 4 and 9
months of antimycobacterial therapy that showed a decreased
FDG accumulation [61]. Drijkoningen et al. reported another
case of regression of PET avidity in disseminated MAC
disease after 2 months of specific therapy [62]. No specific
recommendations exist about the use of PET/CT in the
follow-up of NTM disease, but these reports may indicate a
possible role in both evaluation of successful treatment and
follow-up.
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